再添硬核认证！药明生物成功通过ISO 20400认证，树立可持续采购标杆

中国无锡,

2026年1月5日

药明生物（WuXi Biologics, 2269.HK）宣布，公司已成功通过 ISO 20400 可持续采购体系认证。这一国际标准是全球公认的可持续采购指南，旨在帮助企业将可持续发展原则融入采购流程，推动构建负责任、透明的供应链。此次认证充分体现药明生物在可持续发展领域的卓越表现，以及公司在夯实供应链韧性及可持续采购能力建设方面所做出的不懈努力。

公司已将可持续发展与供应商管理理念深度融合，从尽职调查和准入，到过程中风险管控与持续互动，再到定期责任采购审计与全方位绩效评估，全面构建绿色、透明、可追溯的供应商全生命周期管理流程。这一举措不仅确保供应商始终符合质量、合规与可持续标准，更能有效降低风险、提升运营效率、推动供应商共同履行社会责任。

深知应对气候变化的重要性，药明生物制定一体化战略、科学可量化的SBTi目标矩阵以及清晰路线图，在全力实现自身气候目标的同时，积极携手全球供应商伙伴，推动可持续供应链管理体系建设，驱动整个价值链迈向净零可持续未来。

作为联合国全球契约组织（UNGC）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；荣登CDP气候变化、水安全和供应商参与度三大领域A级榜单；获评晨星Sustainalytics ESG“风险可忽略”最高评级以及“行业最高评级”与“区域最高评级”企业；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。

*PSCI: 制药供应链倡议组织，全球制药和医疗健康领域的领先协会，其核心使命是携手合作伙伴推动负责任价值链构建，实现安全、环境和社会效益方面的卓越表现。

关于药明生物

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

Wuxi, China,

January 5, 2026

WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain. This recognition highlights WuXi Biologics' outstanding performance in sustainability and showcases the company's dedicated efforts in strengthening supply chain resilience.

Dr. Chris Chen

Chief Executive Officer

Chairman of the ESG Committee

WuXi Biologics

WuXi Biologics has embedded sustainability principles across its entire system of supplier lifecycle management — from supplier due diligence and admission, to risk management and engagement, to performance review and termination. This not only ensures that suppliers consistently meet quality, compliance, and sustainability standards throughout their partnerships, but also enables transparent and traceable supply chains, mitigates risks, improves operational efficiency, and drives responsible practices among suppliers.

Deeply understanding the importance of tackling climate change, WuXi Biologics has adopted an integrated strategy with measurable SBTi targets and refined roadmaps. While diligently pursuing its own climate goals, the company also actively engages with suppliers through comprehensive sustainable supply chain management to help achieve positive impacts across the entire value chain.

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

*PSCI: Pharmaceutical Supply Chain Initiative, the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain.